Edwards Lifesciences Corporation Stock News

Strong adoption of the MITRIS RESILIA valve and increased demand for the HemoSphere monitoring platform will likely drive Edwards Lifesciences' (EW) Q4 revenues.

HOLX vs. EW: Which Stock Is the Better Value Option?

IRVINE, Calif. , Jan. 5, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P.

Down 40%+ this year, EW is now trading at levels not seen in years. I believe the sell-off is unjust, and investors over the next few months will benefit immensely.

In the worst year for stocks since the Great Recession, several big names are headed for their worst year on record with just one trading day left in 2022.

It appears to us at Smead Capital Management that investors are behaving in a way that will damage their capital and cause them to suffer stock market failure. In 2022, as the favorite tech stocks of

Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks.

IRVINE, Calif. , Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and s

Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morn

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report.

As investors get ready for Halloween, five broadly held guru stocks that tumbled more than 10% during October are Meta Platforms Inc. ( META , Financial), Amazon.com Inc. ( AMZN , Financial), Alibaba

Although the concept of stocks to buy at the ‘midterm elections' bottom seems farfetched considering the broader volatility this year, the calendar might provide a change of heart. According to The

Edwards Lifesciences has seen shares cut nearly in half from the highs of last year. This is mostly in response to higher interest rates and an overreaction seen towards the upside last year.

Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.